Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT03500159 is registered in ClinicalTrials.gov with Aquinox Pharmaceuticals (Canada) Inc. as lead sponsor.

NCT NCT03500159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03500159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 18, 2018
Completion date
July 17, 2018
Enrollment
3 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pelvic pain syndrome, chronic prostatitis